Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Core Viewpoint - Oncolytics Biotech Inc. has entered into a share purchase agreement with Alumni Capital LP to secure up to US$20 million in funding, aimed at advancing its immunotherapy candidate, pelareorep, while minimizing shareholder dilution [1][2]. Funding Agreement Details - The agreement allows Oncolytics to sell up to US$20 million worth of common stock over a 15-month period, with sales prices based on market conditions at the time of each sale [2]. - Oncolytics retains control over the timing and amount of stock sales, with no associated warrants or derivatives [2]. - The company issued 816,326 commitment shares to Alumni and may issue an additional 816,326 shares upon delivery of purchase notices [2]. Regulatory Approvals - The common shares to be issued under the agreement have received conditional approval for listing on the Toronto Stock Exchange (TSX) [3]. - Required notices related to the share purchase agreement have been filed with Nasdaq [3]. Company Overview - Oncolytics is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent that has shown promising results in treating metastatic breast cancer and pancreatic cancer [8]. - Pelareorep works by inducing anti-cancer immune responses and converting "cold" tumors into "hot" tumors, enhancing treatment efficacy [8]. - The company is planning combination clinical trials with pelareorep and has received Fast Track designation from the FDA for its studies in metastatic breast cancer and pancreatic cancer [9].